Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

By afschroeder • February 19, 2026

Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. JAMA Dermatol. 2026 Feb 18. doi: 10.1001/jamadermatol.2025.6055. Epub ahead of print. PMID: 41706476.

Tags: Dermatology, Publications

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial

Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG. The 487-gene expression[...]

Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma Mimic

Shammas R, Gudino-Rosales S, Kneiber D, Sarantopoulos GP, Aung T. Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma[...]

Assessing workload, compensation, and burnout in academic dermatology: a national multi-institutional survey study

Brinks AL, Lawrence CN, Kearney CA, Maas D, Gillespie C, Adotama P, Senna M, Bordone L, Hordinsky M, Farah R, Aguh C, Mesinkovska N, Colavincenzo[...]